FIRST MULTICENTRIC REAL-LIFE EXPERIENCE WITH THE COMBINATION OF LOMUSTINE AND TEMOZOLOMIDE IN NEWLY DIAGNOSED MGMT PROMOTER METHYLATED IDH WILDTYPE GLIOBLASTOMA

被引：0

作者：

Lazaridis, L. ^{[1
,2
]}

Schmidt, T. ^{[1
,2
]}

Agkatsev, S. ^{[1
,2
]}

Blau, T. ^{[3
]}

Spille, D. ^{[4
]}

Heider, S. ^{[5
]}

Schulz, T. ^{[6
]}

Bumes, E. ^{[7
]}

Oster, C. ^{[1
,2
]}

Feldheim, J. ^{[1
,2
]}

Stummer, W.

Kessler, A. ^{[6
]}

Seidel, C. ^{[5
]}

Hau, P. ^{[7
]}

Sure, U. ^{[8
]}

Keyvani, K. ^{[3
]}

Herrlinger, U. ^{[9
]}

Kleinschnitz, C. ^{[1
,2
]}

Stuschke, M. ^{[10
]}

Herrmann, K. ^{[11
]}

Deuschl, C. ^{[12
]}

Hattingen, E. ^{[13
]}

Scheffler, B. ^{[14
]}

Kebir, S. ^{[1
,2
]}

Glas, M. ^{[1
,2
]}

机构：

[1] Univ Med Essen, Div Clin Neurooncol, Ctr Translat Neuro & Behav Sci C TN, Essen, Germany

[2] Univ Med Essen, Dept Neurol, Essen, Germany

[3] Univ Med Essen, Inst Neuropathol, Essen, Germany

[4] Univ Hosp Munster, Dept Neurosurg, Munster, Germany

[5] Univ Hosp Leipzig, Dept Radiotherapy & Radiat Oncol, Leipzig, Germany

[6] Univ Hosp Wurzburg, Dept Neurosurg, Wurzburg, Germany

[7] Univ Hosp Regensburg, Dept Neurol & Wilhelm Sander NeuroOncol Unit, Regensburg, Germany

[8] Univ Med Essen, Dept Neurosurg & Spine Surg, Essen, Germany

[9] Univ Hosp Bonn, Div Clin Neurooncol, Dept Neurol & Ctr Integrated Oncol, Bonn, Germany

[10] Univ Med Essen, Dept Radiotherapy, Essen, Germany

[11] Univ Med Essen, Dept Nucl Med, Essen, Germany

[12] Univ Med Essen, Inst Diagnost & Intervent Radiol & Neurora, Essen, Germany

[13] Univ Hosp Frankfurt, Inst Neuroradiol, Frankfurt, Germany

[14] Univ Med Essen, West German Canc Ctr WTZ, DKFZ Div Translat Neurooncol, DKTK Partner Site, Essen, Germany

来源：

NEURO-ONCOLOGY | 2022年 / 24卷

关键词：

D O I：

10.1093/neuonc/noac174.204

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P11.15.B

引用

页数：2

共 50 条

[31] Kombination von Lomustin und Temozolomid in der Therapie von Patienten mit neu diagnostizierten MGMT-Promotor-methylierten GlioblastomenCombination therapy of lomustine and temozolomide in patients with newly diagnosed glioblastoma with methylated MGMT promotor
Julia Lenzen
H. J. Feldmann
Der Onkologe, 2019, 25 (12): : 1118 - 1120
[32] Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial
Omuro, Antonio
Brandes, Alba A.
Carpentier, Antoine F.
Idbaih, Ahmed
Reardon, David A.
Cloughesy, Timothy
Sumrall, Ashley
Baehring, Joachim
van den Bent, Martin
Bahr, Oliver
Lombardi, Giuseppe
Mulholland, Paul
Tabatabai, Ghazaleh
Lassen, Ulrik
Sepulveda, Juan Manuel
Khasraw, Mustafa
Vauleon, Elodie
Muragaki, Yoshihiro
Di Giacomo, Anna Maria
Butowski, Nicholas
Roth, Patrick
Qian, Xiaozhong
Fu, Alex Z.
Liu, Yanfang
Potter, Von
Chalamandaris, Alexandros-Georgios
Tatsuoka, Kay
Lim, Michael
Weller, Michael
NEURO-ONCOLOGY, 2023, 25 (01) : 123 - 134
[33] Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial
Weller, Johannes
Tzaridis, Theophilos
Mack, Frederic
Steinbach, Joachim Peter
Schlegel, Uwe
Hau, Peter
Krex, Dietmar
Grauer, Oliver
Goldbrunner, Roland
Baehr, Oliver
Uhl, Martin
Seidel, Clemens
Tabatabai, Ghazaleh
Brehmer, Stefanie
Bullinger, Lars
Galldiks, Norbert
Schaub, Christina
Kebir, Sied
Stummer, Walter
Simon, Matthias
Fimmers, Rolf
Coch, Christoph
Glas, Martin
Herrlinger, Ulrich
Schaefer, Niklas
LANCET ONCOLOGY, 2019, 20 (10): : 1444 - 1453
[34] Treatment-associated imaging changes in newly diagnosed MGMT promoter-methylated glioblastoma undergoing chemoradiation with or without cilengitide
Flies, Christina Maria
Friedrich, Michel
Lohmann, Philipp
van Garderen, Karin Alida
Smits, Marion
Tonn, Joerg-Christian
Weller, Michael
Galldiks, Norbert
Snijders, Tom Jan
NEURO-ONCOLOGY, 2024, 26 (05) : 902 - 910
[35] Recurrence Pattern After Temozolomide Concomitant With and Adjuvant to Radiotherapy in Newly Diagnosed Patients With Glioblastoma: Correlation With MGMT Promoter Methylation Status
Brandes, Alba A.
Tosoni, Alicia
Franceschi, Enrico
Sotti, Guido
Frezza, Giampiero
Amista, Pietro
Morandi, Luca
Spagnolli, Federica
Ermani, Mario
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (08) : 1275 - 1279
[36] A Phase II Trial of Concurrent Sunitinib, Temozolomide and Radiation Therapy Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients with an Unmethylated MGMT Gene Promoter
Faye, M. D.
Sabri, S.
De Robles, P.
Agnihotram, R.
Torres-Vasquez, A.
Panet-Raymond, V.
Shenouda, G.
Souhami, L.
Esaw, J.
Abdulkarim, B. S.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : S169 - S169
[37] Quality of life in the GLARIUS trial randomizing bevacizumab/ irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma
Schaefer, Niklas
Proescholdt, Martin
Steinbach, Joachim P.
Weyerbrock, Astrid
Hau, Peter
Grauer, Oliver
Goldbrunner, Roland
Friedrich, Franziska
Rohde, veit
Ringel, Florian
Schlegel, Uwe
Sabel, Michael
Ronellenfitsch, Michael W.
Uhl, Martin
Grau, Stefan
Haenel, Mathias
Schnell, Oliver
Krex, Dietmar
Vajkoczy, Peter
Tabatabai, Ghazaleh
Mack, Frederic
Schaub, Christina
Tzaridis, Theophilos
Niessen, Michael
Kebir, Sied
Leutgeb, Barbara
Urbach, Horst
Belka, Claus
Stummer, Walter
Glas, Martin
Herrlinger, Ulrich
NEURO-ONCOLOGY, 2018, 20 (07) : 975 - 985
[38] Prognostic role and interaction of TERT promoter status, telomere length and MGMT promoter methylation in newly diagnosed IDH wild-type glioblastoma patients
Giunco, S.
Padovan, M.
Angelini, C.
Cavallin, F.
Cerretti, G.
Morello, M.
Caccese, M.
Rizzo, B.
d'Avella, D.
Puppa, A. D.
Chioffi, F.
De Bonis, P.
Zagonel, V.
De Rossi, A.
Lombardi, G.
ESMO OPEN, 2023, 8 (03)
[39] Randomized phase II/III trial of veliparib or placebo in combination with adjuvant temozolomide in newly diagnosed glioblastoma (GBM) patients with MGMT promoter hypermethylation (Alliance A071102).
Sarkaria, Jann Nagina
Ballman, Karla V.
Kizilbash, Sani Haider
Sulman, Erik P.
Giannini, Caterina
Mashru, Sandeep H.
Piccioni, David Eric
Friday, Bret Edward Buckley
Dixon, Jesse G.
Kabat, Brian
Laack, Nadia N.
Hu, Leland
Kumthekar, Priya
Ellingson, Benjamin M.
Anderson, S. Keith
Galanis, Evanthia
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[40] QUALITY OF LIFE IN THE PHASE III CeTeG/NOA-09 TRIAL RANDOMIZING CCNU/TEMOZOLOMIDE (TMZ) COMBINATION THERAPY VS. STANDARD TMZ THERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED GLIOBLASTOMA
Weller, Johannes
Tzaridis, Theophilos
Steinbach, Joachim
Schlegel, Uwe
Hau, Peter
Krex, Dietmar
Grauer, Oliver
Goldbrunner, Roland
Baehr, Oliver
Uhl, Martin
Seidel, Clemens
Tabatabai, Ghazaleh
Bullinger, Lars
Galldiks, Norbert
Schaub, Christina
Stummer, Walter
Simon, Matthias
Fimmers, Rolf
Matthias, Schmid
Coch, Christoph
Glas, Martin
Herrlinger, Ulrich
Schaefer, Niklas
NEURO-ONCOLOGY, 2018, 20 : 218 - 219

← 1 2 3 4 5 →